Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Undisclosed
Partner/Sponsor/Collaborator: Permira Funds
Deal Size: $1,880.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 22, 2020
The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.